ArticleOncogene2011
Genome-wide shRNA screen reveals increased mitochondrial dependence upon mTORC2 addiction.
Article in Oncogene, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 48 citations in OpenAlex.
- The Pathophysiological Role of Mitochondria-associated Membranes in Coronary Artery Disease and Atherosclerosis.Current medicinal chemistry · 2026Review
- The mTORC2 signaling network: targets and cross-talks.The Biochemical journal · 2024Review
- Mitochondria-associated endoplasmic reticulum membranes as a therapeutic target for cardiovascular diseases.Frontiers in pharmacology · 2024Review
- Review
- Redox Systems Biology in Chronic Kidney Disease.Oxidative medicine and cellular longevity · 2023Article
- NAD/NAMPT and mTOR Pathways in Melanoma: Drivers of Drug Resistance and Prospective Therapeutic Targets.International journal of molecular sciences · 2022Review
- Metabolism heterogeneity in melanoma fuels deactivation of immunotherapy: Predict before protect.Frontiers in oncology · 2022Review
- Regulation and metabolic functions of mTORC1 and mTORC2.Physiological reviews · 2021Review
- The Mitochondrial-Associated Endoplasmic Reticulum Membrane and Its Role in Diabetic Nephropathy.Oxidative medicine and cellular longevity · 2021Review
- Regulation of mTORC2 Signaling.Genes · 2020Review
- Review
- Mitochondria-Associated Endoplasmic Reticulum Membranes in Cardiovascular Diseases.Frontiers in cell and developmental biology · 2020Review
- mTORC1 and mTORC2 as regulators of cell metabolism in immunity.FEBS letters · 2017Review
- MEDICI: Mining Essentiality Data to Identify Critical Interactions for Cancer Drug Target Discovery and Development.PloS one · 2017Article
- Syrosingopine sensitizes cancer cells to killing by metformin.Science advances · 2016Article
- mTOR and differential activation of mitochondria orchestrate neutrophil chemotaxis.The Journal of cell biology · 2015Article
- Where is mTOR and what is it doing there?The Journal of cell biology · 2013Review
- Senescence and aging: the critical roles of p53.Oncogene · 2013Review
- Feature Article: mTOR complex 2-Akt signaling at mitochondria-associated endoplasmic reticulum membranes (MAM) regulates mitochondrial physiology.Proceedings of the National Academy of Sciences of the United States of America · 2013Article
- An arrayed genome-scale lentiviral-enabled short hairpin RNA screen identifies lethal and rescuer gene candidates.Assay and drug development technologies · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Release from growth factor dependence and acquisition of signalling pathway addiction are critical steps in oncogenesis. To identify genes required on mammalian target of rapamycin (mTOR) addiction, we performed a genome-wide short hairpin RNA screen on a v-H-ras-transformed Pten-deficient cell line that displayed two alternative growth modes, interleukin (IL)-3-independent/mTOR-addicted proliferation (transformed growth mode) and IL-3-dependent/mTOR-non-addicted proliferation (normal growth mode). We screened for genes required only in the absence of IL-3 and thus specifically for the transformed growth mode. The top 800 hits from this conditional lethal screen were analyzed in silico and 235 hits were subsequently rescreened in two additional Pten-deficient cell lines to generate a core set of 47 genes. Hits included genes encoding mTOR and the mTOR complex 2 (mTORC2) component rictor and several genes encoding mitochondrial functions including components of the respiratory chain, adenosine triphosphate synthase, the mitochondrial ribosome and mitochondrial fission factor. Small interfering RNA knockdown against a sizeable fraction of these genes triggered apoptosis in human cancer cell lines but not in normal fibroblasts. We conclude that mTORC2-addicted cells require mitochondrial functions that may be novel drug targets in human cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.